Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Gene set analysis of purine and pyrimidine antimetabolites cancer therapies.

Pharmacogenetics and genomics - 1 Nov 2011

Fridley Brooke L, Batzler Anthony, Li Liang, Li Fang, Matimba Alice, Jenkins Gregory D, Ji Yuan, Wang Liewei, Weinshilboum Richard M

Abstract excerpt

OBJECTIVE: Responses to therapies, either with regard to toxicities or efficacy, are expected to involve complex relationships of gene products within the same molecular pathway or functional gene set. Therefore, pathways or gene sets, as opposed to single genes, may better reflect the true underlying biology and may be more appropriate units for analysis of pharmacogenomic studies. Application of such methods to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antimetabolites
Share to Area Under Curve

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Deoxycytidine

Share to Gemcitabine

Share to Genes, Neoplasm

Share to Purines

Share to Pyrimidines

Share to Thioguanine

Source

Open in PubMed Open full text

Identifiers

PMID: 21869733
DOI: 10.1097/FPC.0b013e32834a48a9
PMCID: PMC3192305

Genes

ADRM1
CANT1
ENTPD6
PSME3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Gene set analysis of purine and pyrimidine antimetabolites cancer therapies.PMID 21869733Read ↗

Gemcitabine and Cytosine Arabinoside Cytotoxicity: Association with Lymphoblastoid Cell ExpressionSemantic proximity Read ↗

Gemcitabine and arabinosylcytosin pharmacogenomics: genome-wide association and drug response biomarkers.Semantic proximity Read ↗

Copy number variation and cytidine analogue cytotoxicity: a genome-wide association approach.Semantic proximity Read ↗

Thiopurine pharmacogenomics: association of SNPs with clinical response and functional validation of candidate genes.Semantic proximity Read ↗

Systems therapeutics analyses identify genomic signatures defining responsiveness to allopurinol and combination therapy for lung cancerSemantic proximity Read ↗

Genetic and epigenetic variants contributing to clofarabine cytotoxicity.Semantic proximity Read ↗

Cytosolic 5'-nucleotidase III (NT5C3): gene sequence variation and functional genomics.Semantic proximity Read ↗

Discovery of genetic biomarkers contributing to variation in drug response of cytidine analogues using human lymphoblastoid cell lines.Semantic proximity Read ↗

Mycophenolic acid response biomarkers: a cell line model system-based genome-wide screen.Semantic proximity Read ↗

Molecular features that predict the response to antimetabolite chemotherapiesSemantic proximity Read ↗

Heritable and non-genetic factors as variables of pharmacologic phenotypes in lymphoblastoid cell lines.Semantic proximity Read ↗

Role of cytidine deaminase in toxicity and efficacy of nucleosidic analogs.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.